Tissue Regenix Group PLC Issue of Equity & Total Voting Rights Replacement (8733J)
December 24 2020 - 6:56AM
UK Regulatory
TIDMTRX
RNS Number : 8733J
Tissue Regenix Group PLC
24 December 2020
Tissue Regenix Group plc
Issue of Equity and Total Voting Rights - Replacement
Correction to announcement released at 09.51 on 23 December 2020
under RNS reference 6693J. The original announcement incorrectly
stated that the nominal value of shares issued and allotted was
0.5p when it should have stated 0.1p. The corrected announcement is
set out below. No other information has been updated.
Leeds, 23 December 2020 - Tissue Regenix Group plc (AIM:TRX)
("the Company"), the regenerative medical devices company,
announces that it has issued and allotted 91,743 ordinary shares of
0.1p each in the Company, following an exercise of options which
were granted in respect of the 2018 DAB option scheme.
The 91,743 new ordinary shares will rank pari passu with the
existing ordinary shares and application will shortly be made for
these new ordinary shares to be admitted to trading on AIM. It is
expected that Admission will occur at 8:00a.m. on 31 December
2020.
Total Voting Rights
Following the issue of the 91,743 new ordinary shares, the
Company will have a total of 7,033,077,499 ordinary shares of 0.1p
each in issue. The above figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3052
Caitlin Pearson Head of Communications
------------------------------------------ --------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Ben Maddison / Alex Price
------------------------------------------ --------------------
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEEAAALASEEFFA
(END) Dow Jones Newswires
December 24, 2020 07:56 ET (12:56 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024